MET and small cell lung carcinoma: This is associated with second-site mutations in the EGFR kinase gene (e.g., T790M), amplification of alternative kinases (e.g., mesenchymal-epithelial transition factor, MET), histologic transformation to small cell lung cancer (SCLC), and epithelial to mesenchymal transition.